Replies to post #189967 on Biotech Values

[biocqr]

The proportion of patients with a VA gain of >=3 lines (15 letters) is the most common primary endpoint in wet AMD

In the ranibizumab P3 trials, ANCHOR and MARINA, the primary endpoint was the proportion of patients losing <15 letters from baseline VA at 12 months... not gaining >15 letters... big difference.

http://www.lucentis.com/hcp/amd/efficacy-amd.html